Context: How B3 (Brasil, Bolsa, Balcao) works, and what it makes issuers disclose · Brazil on the LatAm Power Map
Brazil’s scan-and-test network Allianças Saúde — known on the street as Alliar — runs imaging machines and lab benches across the country for more than a billion reais a year. The company has gone three straight years without a profit; whether it can finally turn the corner is the question every shareholder is asking.
| Full name | Alliança Saúde e Participações S.A. (formerly Centro de Imagem Diagnósticos S.A.) |
| Ticker / exchange | AALR3 · B3 (São Paulo) |
| Headquarters | Rua Afonso de Freitas 59, Paraíso, São Paulo, SP, Brazil |
| Sector | Healthcare — Diagnostics & Research |
| Employees | Not disclosed in available sources |
| Market value (market cap) | R$490.5m (~US$94.2m) |
| Yearly sales (revenue, 2024) | R$1.217bn (~US$233.8m) |
| Net profit / loss (2024) | –R$129.1m (~–US$24.8m) |
| Net margin (2024) | –10.6% (our calculation) |
| Return on equity (2024) | –11.8% (our calculation); –6.2% on trailing basis (EODHD) |
| Price-to-earnings ratio | N/A — company is loss-making |
| Dividend yield | None |
| Website | allianca.com · IR: ri.allianca.com |
What it is
Allianças Saúde was founded in 1992 and operated under the name Centro de Imagem Diagnósticos — popularly called “Alliar” — until April 2023, when it adopted its current name. It provides diagnostic imaging and clinical-medicine services across Brazil, covering MRI, CT scans, PET-CT, ultrasound, nuclear medicine, genetic testing, vaccination and laboratory analysis, serving both private and public sector hospitals and diagnostic centres.
The company operates units in the states of Paraná, Pará, Minas Gerais, Bahia, Espírito Santo, Rio de Janeiro, Rio Grande do Norte and São Paulo, among others. Its offer is essentially B2B-plus-retail: patients walk in, but contracts with health plans and hospitals drive the volumes.
Who owns it
The controlling shareholder is Fonte de Saúde Fundo de Investimento em Participações Multiestratégia (“Fonte de Saúde FIP”), whose controlling quota-holder is Lormont Participação S.A. Together these two entities form the ownership chain that controls the company. According to EODHD data, insiders hold about 7.8% of shares directly, while institutional investors control 91.3% of the float — meaning this is effectively an institutionally-held stock with a tightly structured controlling block at the top.
Who runs it
The company has seen considerable executive churn. The Board of Directors elected Ms.
Karla Maciel Dolabella, then CFO and Investor Relations Officer, to temporarily step in as CEO after the previous chief executive resigned. That was followed by the election of Pedro Thompson as CEO.
The investor-relations site (read July 2026) now lists José Luiz Mendes Ramos Junior as Chief Legal, Compliance and Investor Relations Officer, elected April 2025 with a term to the 2027 shareholders’ meeting; the current CEO is not disclosed by name on the public executive page as of this writing.
The money, in plain words
Sales grew 3.2% in 2024 to R$1.217bn (~US$233.8m), a slowdown from the 8.7% growth recorded in 2023 (our calculations). For every real of sales, the company keeps about 29 cents after paying direct costs — a gross margin of 29.2% — but once interest and other expenses are counted, it loses roughly 11 cents on every real earned: a net loss margin of –10.6% (our calculation).
The net loss shrank sharply, from R$227.9m (~US$43.8m) in 2023 to R$129.1m (~US$24.8m) in 2024 — still a heavy deficit, but the trajectory is improving. The company carries R$951m (~US$182.7m) in total debt against only R$115m (~US$22.1m) in cash, leaving a net debt position of R$836m (~US$160.6m) — our calculation — which is the central financial risk investors are watching.
What it is doing now
Operating income turned positive in 2024 — R$107.1m (~US$20.6m) against a near-zero R$38.9m (US$7 mn) in 2023 and a loss in 2022 — showing that the core scanning and testing business is generating cash before debt costs. The remaining gap between operating profit and net loss is almost entirely the interest bill on that R$836m (US$161 mn) net debt pile.
In 2023 the controlling bloc (Fonte de Saúde FIP and Lormont) launched a formal tender offer (OPA) process, filing with the CVM and B3. The outcome of that process, which aimed to restructure the company’s capital and ownership, continues to shape the stock’s trading dynamics.
What to watch
- Debt refinancing. With net debt of R$836m (~US$160.6m) and interest costs swallowing all operating profit, any change in borrowing costs or debt terms will move the bottom line faster than any revenue gain.
- Leadership continuity. Multiple CEO changes in three years signal governance stress; the market will reward stability.
- Revenue momentum. Growth slowed to 3.2% in 2024 from 8.7% in 2023; a return to faster growth — driven by more public-sector contracts or new geographies — is needed to outgrow the debt burden.
- Path to profit. The operating income line is now positive for the first time in three years; a further improvement in 2025 would test whether the turnaround is real or fragile.
- OPA resolution. The outcome of the controlling shareholders’ tender offer process may alter the free float, governance structure, and minority-shareholder rights.
Sources
- Alliança Saúde Investor Relations — Executive Officers (primary governance page, read July 2026): ri.allianca.com/en/corporate-governance/executive-officers/
- Alliança Saúde IR — Material Fact: New CFO and IRO (October 2022): ri.allianca.com/en/noticias/material-fact-new-cfo-and-iro/
- Alliança Saúde IR — Resignation as Chief Executive Officer (2022): ri.allianca.com/en/noticias/resignation-as-chief-executive-officer/
- MarketScreener — Material Fact: New OPA Protocol (March 2023), sourced from company B3 filing: marketscreener.com
- Market data: EODHD.
This is news, not investment advice.
Read More from The Rio Times